February 13, 2015 — Boston Scientific and C. R. Bard announced a deal where Boston Scientific will distribute the Lutonix 035 drug coated balloon (DCB) percutaneous transluminal angioplasty catheter in the United States under a limited distribution agreement reached with Bard. Terms of the agreement were not disclosed.
The Lutonix DCB is an angioplasty balloon coated with a therapeutic dose of the drug paclitaxel that is designed to decrease the incidence of restenosis and improve patency in patients with stenosed femoropopliteal vessels, often seen with peripheral artery disease. Lutonix DCB was the first U.S. Food and Drug Administration (FDA)-approved DCB in the United States.
For more information: www.bostonscientific.com, www.crbard.com
June 13, 2024 
